GO
Loading...

Abbott Laboratories

More

  • The Week:  Saving the Worst For Last Saturday, 12 Apr 2008 | 7:31 AM ET
    Stocks down

    A steady stream of downbeat news seemed to leave the market unmoved for most of the week -- until the bluest of the blue chips, General Electric, posted first-quarter earnings that missed Wall Street expectations by seven cents per share, and lowered its full-year guidance.  

  • Week Ahead: Challenging -- At The Least Friday, 11 Apr 2008 | 7:34 PM ET

    A double helping of economic data and first-quarter earnings reports will flood the zone next week, but it's the corporate earnings that will drive stocks and give a better picture of where the economy is going. If GE's bombshell earnings miss is an indicator, the news will be as nasty as traders expect.

  • Japan's Takeda to Buy Millennium Pharma Thursday, 10 Apr 2008 | 6:25 AM ET

    Takeda Pharmaceutical said it would buy U.S. firm Millennium Pharmaceuticals for $8.8 billion to boost its cancer drug business, in the biggest overseas acquisition by a Japanese drug maker.

  • Defensive Stock Picks for a Rebound Monday, 7 Apr 2008 | 1:22 PM ET

    After a rough start, top investment officers are looking for gradual improvement as 2008 goes on.  Harbor Advisory's Jack DeGan is among them, and he won't sugar-coat the current situation.

  • Stocks End on High Note But Quarter Is Sour Monday, 31 Mar 2008 | 5:17 PM ET

    Stocks advanced Monday, led by financials, as the market looked for insight into the second quarter and braced for closing its worst quarter in 5 1/2 years.

  • Financials Lead Rebound; Merck Skids Monday, 31 Mar 2008 | 2:16 PM ET

    Stocks advanced Monday, led by financials, as the market looked for insight into the second quarter and braced for closing its worst quarter in 5 1/2 years.

  • Drug Stock Scorecard: MRK, SGP Losers--Pfizer A Winner Monday, 31 Mar 2008 | 11:35 AM ET

    Who’s the winner and loser in drug stocks today? Schering-Plough down 25 percent (!) and Merck down 16 percent pre-open on a study that showed that the companies cholesterol lowering drugs Vytorin and Zetia were not more effective than less expensive drugs.

  • Market-Moving Murmurs Thursday, 27 Mar 2008 | 6:30 PM ET

    The American College Of Cardiology kicks off its annual meeting in Chicago on Saturday. What’s the trade ahead of this major meeting of heart doctors?

  • J&J, Boston Scientific, Medtronic & Abbott: Stent "Stuff" Thursday, 27 Mar 2008 | 10:50 AM ET
    Heart Stent

    Ahead of the world's biggest gathering of cardiologists in Chicago this weekend, there's a flurry of news about stents--the expensive little wire mesh tubes that prop open clogged arteries. First, the Food and Drug Administration has posted new proposed guidelines for pre-and post-market testing of the controversial devices.

  • Lightning Round: Bear Stearns, Disney, Costco and More Thursday, 6 Mar 2008 | 7:23 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Lightning Round OT: Allergan and More Thursday, 6 Mar 2008 | 7:23 PM ET

    The Lightning Round is extended in this new CNBC.com exclusive feature.

  • What's an Investor to Do? Recession-Proof Stocks Tuesday, 5 Feb 2008 | 3:35 PM ET

    Investors are worried about a recession again.  So  CNBC asked the experts for some recession-proof stock picks.

  • Medical Device Makers: Healthy Buys Tuesday, 5 Feb 2008 | 3:01 PM ET

    The medical device field has its problems -- but Jan Wald thinks the stocks of medical device makers may be excellent defensive plays in the current market environment. "Valuations of these stocks are pretty low at this point," the Stanford Group managing director told CNBC...

  • Boston Scientific And The "Struggling" Stents Tuesday, 5 Feb 2008 | 10:25 AM ET

    Sales of drug-coated stents, Boston Scientific's most profitable products, came in at the low end of the company's guidance in the fourth quarter. Stents are the fragile little wire mesh cylinders that act like scaffolding to prop open clogged arteries.

  • An unprecedented late-day rally reversed morning losses and sent the Dow higher by 300 points - all thanks to the banks and brokers. Could this move mean a bottom or is it nothing more an oversold rally?

  • Stocks Snap Losing Streak With Huge Rally Wednesday, 23 Jan 2008 | 3:08 PM ET

    Stocks snapped a five-day losing streak, with the Dow surging nearly 300 points on optimism that a government plan to rescue ailing bond insurers is taking shape and could prevent billions more in credit losses.

  • Goldman Sachs: The "Safe" Stocks For Primary Season Monday, 7 Jan 2008 | 4:20 PM ET

    Goldman Sachs analysts say stock investors should look to larger cap and defensive sectors as a way to play the uncertainty of presidential primary season. While they say the major party nominees should become clear by "Super Duper Tuesday," there is greater electoral and policy uncertainty in this Presidential race because there are no incumbents running.

  • My 7 For '07: The Pharma Year in Review Friday, 28 Dec 2007 | 1:57 PM ET

    The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.

  • Friday's Playbook Thursday, 27 Dec 2007 | 7:29 PM ET

    Like precision radar, The Fast Money Five zero in on three hot trades. Find out how they're playing excessive write-downs, a highly anticipated decision from the FDA and avoiding a visit from the tax man!

  • Abbott Labs Cuts 1,200 Jobs as Stent Market Ebbs Tuesday, 4 Dec 2007 | 8:33 PM ET

    Abbott Laboratories said on Tuesday it will lay off about 1,200 workers in California and Ireland to compensate for a contracting drug-coated heart stent market and manufacturingimprovements.